JP2009539882A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009539882A5 JP2009539882A5 JP2009514564A JP2009514564A JP2009539882A5 JP 2009539882 A5 JP2009539882 A5 JP 2009539882A5 JP 2009514564 A JP2009514564 A JP 2009514564A JP 2009514564 A JP2009514564 A JP 2009514564A JP 2009539882 A5 JP2009539882 A5 JP 2009539882A5
- Authority
- JP
- Japan
- Prior art keywords
- chor
- independently
- compound
- lower alkyl
- cap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 150000002431 hydrogen Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 108010052164 Sodium Channels Proteins 0.000 claims 4
- 102000018674 Sodium Channels Human genes 0.000 claims 4
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 4
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 4
- -1 methylenedioxy group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 229930182480 glucuronide Natural products 0.000 claims 3
- 230000036571 hydration Effects 0.000 claims 3
- 238000006703 hydration reaction Methods 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 2
- 108010078678 Osmolite Proteins 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 229940124630 bronchodilator Drugs 0.000 claims 2
- 239000000168 bronchodilator agent Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 230000018044 dehydration Effects 0.000 claims 2
- 238000006297 dehydration reaction Methods 0.000 claims 2
- 206010013781 dry mouth Diseases 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 101100240517 Caenorhabditis elegans nhr-11 gene Proteins 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 206010013786 Dry skin Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 241000792859 Enema Species 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 102100028045 P2Y purinoceptor 2 Human genes 0.000 claims 1
- 101710096700 P2Y purinoceptor 2 Proteins 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 230000001713 cholinergic effect Effects 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 230000037336 dry skin Effects 0.000 claims 1
- 239000007920 enema Substances 0.000 claims 1
- 229940095399 enema Drugs 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 150000008134 glucuronides Chemical class 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 208000003243 intestinal obstruction Diseases 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 230000008881 mucosal defense Effects 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81207706P | 2006-06-09 | 2006-06-09 | |
| US60/812,077 | 2006-06-09 | ||
| PCT/US2007/070861 WO2007146869A1 (en) | 2006-06-09 | 2007-06-11 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009539882A JP2009539882A (ja) | 2009-11-19 |
| JP2009539882A5 true JP2009539882A5 (https=) | 2010-07-29 |
| JP5254961B2 JP5254961B2 (ja) | 2013-08-07 |
Family
ID=38832114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009514564A Expired - Fee Related JP5254961B2 (ja) | 2006-06-09 | 2007-06-11 | ベータアゴニスト活性を有するフェニル置換ピラジノイルグアニジンナトリウムチャネル遮断薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8163758B2 (https=) |
| EP (1) | EP2035004B1 (https=) |
| JP (1) | JP5254961B2 (https=) |
| AU (1) | AU2007257781B2 (https=) |
| CA (1) | CA2654244A1 (https=) |
| DK (1) | DK2035004T3 (https=) |
| ES (1) | ES2392999T3 (https=) |
| NO (1) | NO20085128L (https=) |
| PL (1) | PL2035004T3 (https=) |
| PT (1) | PT2035004E (https=) |
| SI (1) | SI2035004T1 (https=) |
| WO (1) | WO2007146869A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858615B2 (en) * | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| AU2004266704B2 (en) | 2003-08-18 | 2012-02-23 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| US7807834B2 (en) | 2005-08-03 | 2010-10-05 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| KR100901664B1 (ko) | 2007-08-06 | 2009-06-09 | 주식회사 오스코텍 | β-아미노알콜 유도체, 이의 제조방법 및 이를유효성분으로 함유하는 ＴＮＦ-α 매개성 질환의 예방 및치료용 약학적 조성물 |
| DE102007040615A1 (de) * | 2007-08-27 | 2009-03-05 | Bitop Ag | Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen |
| US8551534B2 (en) | 2007-10-10 | 2013-10-08 | Parion Sciences, Inc. | Inhaled hypertonic saline delivered by a heated nasal cannula |
| DE102007052380A1 (de) * | 2007-10-31 | 2009-05-07 | Bitop Ag | Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten |
| WO2009139948A1 (en) | 2008-02-26 | 2009-11-19 | Johnson Michael R | Poly aromatic sodium channel blockers |
| UY33373A (es) | 2010-05-10 | 2011-12-30 | Gilead Sciences Inc | ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?. |
| CA2796826A1 (en) | 2010-05-10 | 2011-11-17 | Gilead Sciences, Inc. | Bifunctional quinoline derivatives |
| WO2012032546A2 (en) * | 2010-09-08 | 2012-03-15 | Cadila Healthcare Limited | Process for the preparation of salmeterol and its intermediates |
| DE102011103347B4 (de) * | 2011-05-27 | 2014-10-30 | Meda Pharma Gmbh & Co. Kg | Nasale pharmazeutische Formulierung |
| US8778383B2 (en) | 2011-06-07 | 2014-07-15 | Parion Sciences, Inc. | Methods of treatment |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| AR086745A1 (es) * | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| HUE032851T2 (en) | 2011-06-27 | 2017-11-28 | Parion Sciences Inc | A chemically and metabolically stable dipeptide having strong sodium channel blocking activity |
| MX2014014648A (es) | 2012-05-29 | 2015-09-04 | Parion Sciences Inc | Aminoamidas tipo dendrimero que poseen actividad bloqueadora del canal de sodio para el tratamiento de ojo reseco y otras enfermedades mucosas. |
| RU2018138195A (ru) | 2012-12-17 | 2018-12-18 | Пэрион Сайенсиз, Инк. | Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида |
| ES2674665T3 (es) * | 2012-12-17 | 2018-07-03 | Parion Sciences, Inc. | Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida |
| SG10201708931XA (en) | 2012-12-17 | 2017-12-28 | Parion Sciences Inc | Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration |
| SG11201601291QA (en) | 2013-08-23 | 2016-03-30 | Parion Sciences Inc | Dithiol mucolytic agents |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| GB201406225D0 (en) * | 2014-04-07 | 2014-05-21 | Hall Roderick L | Treatment for respiratory disease |
| US20150376145A1 (en) | 2014-06-30 | 2015-12-31 | Parion Sciences, Inc. | Stable sodium channel blockers |
| KR20170108088A (ko) | 2015-01-30 | 2017-09-26 | 패리온 사이언스 인코퍼레이티드 | 신규 모노티올 점액용해제 |
| JP2018520986A (ja) | 2015-04-30 | 2018-08-02 | パリオン・サイエンシィズ・インコーポレーテッド | ジチオール粘液溶解剤の新規なプロドラッグ |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR034000A0 (en) * | 2000-09-25 | 2000-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
| US6858614B2 (en) * | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenolic guanidine sodium channel blockers |
| US6858615B2 (en) * | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US6903105B2 (en) * | 2003-02-19 | 2005-06-07 | Parion Sciences, Inc. | Sodium channel blockers |
| US7268147B2 (en) * | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
| GB0312832D0 (en) * | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| US20050090505A1 (en) * | 2003-08-18 | 2005-04-28 | Johnson Michael R. | Methods of reducing risk of infection from pathogens |
| US7375107B2 (en) * | 2003-08-18 | 2008-05-20 | Parion Sciences, Inc. | Alaphatic pyrazinoylguanidine sodium channel blockers |
| JP2007502829A (ja) * | 2003-08-18 | 2007-02-15 | パリオン・サイエンシィズ・インコーポレーテッド | 環状ピラジノイルグアニジンナトリウムチャネルブロッカー |
| AU2004266704B2 (en) | 2003-08-18 | 2012-02-23 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| US7745442B2 (en) * | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| US7399766B2 (en) * | 2004-08-18 | 2008-07-15 | Parion Sciences, Inc. | Soluble amide & ester pyrazinoylguanidine sodium channel blockers |
| WO2006023617A2 (en) * | 2004-08-18 | 2006-03-02 | Johnson Michael R | Cyclic amide & ester pyrazinoylguanidine sodium channel blockers |
| US20070021439A1 (en) * | 2005-07-25 | 2007-01-25 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers |
| US7807834B2 (en) * | 2005-08-03 | 2010-10-05 | Parion Sciences, Inc. | Capped pyrazinoylguanidine sodium channel blockers |
| AU2007294547A1 (en) * | 2006-09-07 | 2008-03-13 | Parion Sciences, Inc. | Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes |
| US20080293740A1 (en) * | 2007-04-03 | 2008-11-27 | Parion Sciences, Inc. | Method of treating acid-sensing ion channel mediated pain, cough suppression, and central nervous system disorders |
| US8288391B2 (en) * | 2007-04-03 | 2012-10-16 | Parion Sciences, Inc. | Pyrazinoylguanidine compounds for use as taste modulators |
-
2007
- 2007-06-11 PT PT07784388T patent/PT2035004E/pt unknown
- 2007-06-11 WO PCT/US2007/070861 patent/WO2007146869A1/en not_active Ceased
- 2007-06-11 US US12/304,006 patent/US8163758B2/en not_active Expired - Fee Related
- 2007-06-11 ES ES07784388T patent/ES2392999T3/es active Active
- 2007-06-11 JP JP2009514564A patent/JP5254961B2/ja not_active Expired - Fee Related
- 2007-06-11 CA CA002654244A patent/CA2654244A1/en not_active Abandoned
- 2007-06-11 EP EP07784388A patent/EP2035004B1/en not_active Not-in-force
- 2007-06-11 DK DK07784388.6T patent/DK2035004T3/da active
- 2007-06-11 PL PL07784388T patent/PL2035004T3/pl unknown
- 2007-06-11 SI SI200731054T patent/SI2035004T1/sl unknown
- 2007-06-11 AU AU2007257781A patent/AU2007257781B2/en not_active Ceased
-
2008
- 2008-12-09 NO NO20085128A patent/NO20085128L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009539882A5 (https=) | ||
| WO2005018644B1 (en) | Capped pyrazinoylguanidine sodium channel blockers | |
| CA2509981A1 (en) | Hetero substitued sodium channel blockers | |
| WO2005025496B1 (en) | Aliphatic pyrazinoylguanidine sodium channel blockers | |
| KR101654549B1 (ko) | 다중방향족 나트륨 채널 차단제 | |
| JP2010502739A5 (https=) | ||
| AU2009225374B2 (en) | Sodium channel blockers | |
| JP2018505163A5 (https=) | ||
| JP2025512474A5 (https=) | ||
| KR20080043773A (ko) | 신규 캡핑된 피라지노일구아니딘 나트륨 채널 차단제 | |
| KR20070051282A (ko) | 가용성 아미드 및 에스테르 피라지노일구아니딘 나트륨채널 차단제 | |
| KR20060037450A (ko) | 사이클릭 피라지노일구아니딘 나트륨 채널 차단제 | |
| TWI798435B (zh) | 基質金屬蛋白酶(mmp)抑制劑及其使用方法 | |
| JP2018520986A5 (https=) | ||
| HK40009256B (en) | Novel therapeutic agents for the treatment of hbv infection | |
| HK1070369B (en) | Sodium channel blockers | |
| HK1078240B (en) | Hetero substitued sodium channel blockers | |
| HK1088531B (en) | Capped pyrazinoylguanidine sodium channel blockers | |
| HK1088531A (en) | Capped pyrazinoylguanidine sodium channel blockers |